ResearcherBahçeşehir UniversityActive in the last 2 years
Didem Taştekin
Matched on ORCID iD 0000-0002-9522-9849; OpenAlex author ID A5047744191. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 8
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 4
- A Pilot Study of Exploring miRNA-Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implications for Diagnosis and Prognosis. Last author DOI 10.3390/diagnostics15192479↗
- Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma? Last author DOI 10.4103/jcrt.jcrt_469_23↗
- FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Co-author DOI 10.1080/1120009x.2022.2026125↗
- Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s13277-013-0931-8↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Senem Karabulut · 3 shared papers, 2013–2025 · strength 0.60
- Paper A Pilot Study of Exploring miRNA-Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implication… DOI 10.3390/diagnostics15192479↗
- Paper Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma? DOI 10.4103/jcrt.jcrt_469_23↗
- Paper Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. DOI 10.1007/s13277-013-0931-8↗
- Sena Şen · 1 shared paper, 2025 · strength 0.30
- Çiğdem Usul Afşar · 1 shared paper, 2024 · strength 0.26
- Seval Ay Ersoy · 1 shared paper, 2022 · strength 0.15
- Mahmut Gümüş · 1 shared paper, 2022 · strength 0.15
- Faruk Taş · 1 shared paper, 2013 · strength 0.04
- İbrahim Yıldız · 1 shared paper, 2013 · strength 0.04
- Derya Duranyıldız · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.